Generics increase competition: study
The study by an MIT professor and Analysis Group researchers reportedly confirmed that the increase in generics had not reduced incentives to challenge brand name patents.
The regulator is providing examples of appropriate off-label communications.
The agency issued 11 enforcement letters last year.
Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal